CF102

DRUG3 trials

Sponsors

Can-Fite BioPharma

Conditions

Hepatocellular CarcinomaNon-alcoholic Steatohepatitis (NASH)

Phase 1

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

CompletedNCT00790218

Can-Fite BioPharmaHepatocellular Carcinoma

Start: 2009-02-28End: 2013-12-31Updated: 2022-05-17

Phase 2

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

CompletedNCT02128958

Can-Fite BioPharmaHepatocellular Carcinoma

Start: 2014-09-30End: 2021-12-31Updated: 2022-10-04

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

CompletedNCT02927314

Can-Fite BioPharmaNon-alcoholic Steatohepatitis (NASH)

Start: 2017-11-27End: 2020-03-01Updated: 2020-03-17

Related Papers

A novel approach for the treatment of advanced hepatocellular carcinoma (HCC).

JCO Global Oncology2023-08-01

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study

BMJ Open2022-07-013 citations

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

Alimentary Pharmacology & Therapeutics2021-10-2038 citations

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

BMJ Open2020-09-018 citations

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A<sub>3</sub> adenosine receptor agonist (A<sub>3</sub>AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2019-05-2011 citations